elicits a weak antibody & T-cell response in some people; no longer undergoing trials as an Aids Vaccine; studies are underway to examine HIVAC-1e in vaccinia-naive persons; recombinant vaccine using a vaccinia vector & gp160; coordinate with HIV envelope protein gp160(NM)